Turing Technology was founded in 2016 by two world-class applied mathematicians with a long history of innovation and entrepreneurism.
Turing is not an investment management or advice firm. It is a technology company that licenses its technology and Intellectual Property to investment management, insurance, brokerage, and RIA/wealth firms to allow them to create and deliver superior investment solutions.
A principal component of Turing's industry changing technologies includes its Hercules System™, a first-of-its-kind technology that accurately replicates the security holdings and portfolio weights of public mutual funds on a real-time basis.
Residing in Turing's database are replicated holdings of more than 1,000 actively managed mutual funds, from 280+ fund firms, and reflecting $4+ trillion in fund assets under management. Turing has the capacity to accurately replicate more than 2,000 mutual funds.
Turing has proven through independent analysis that the Hercules System's fund replication accuracy is an order of magnitude improvement over any other replication technology in the industry, with an average correlation between the funds' NAVs and Turing's replicated versions of 99.4%.
The ability to see inside, on a real-time basis, virtually every actively managed US equity fund in the country provides Turing – and its clients – unique diagnostic insights into how active investment management functions, as well as providing a nearly unmatched information advantage for the creation of new investment solutions. Turing is deploying this technology to reshape active investment management on multiple fronts.
Turing's primary applications include:
- Ensemble Active Management ("EAM"): a transformative approach to active investment management;
- Data Publishing: custom reports based on the Hercules System's fund replication output, including our proprietary Stock Pickers Skill report;
- Variable Annuity Hedging: solution providing the means to identify, measure, and then effectively hedge the stock-specific basis risk that remains outside of insurance firms' beta-centric hedging operations.